Clinical Trial Update: IP3R Modulation by Cancer Genes in Mesothelioma

View source ↗

Summary

A KU Leuven-sponsored clinical trial investigates modulation of IP3R by cancer genes in malignant mesothelioma; the current status of the study is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Snippet

Sponsor: KU Leuven | Conditions: Malignant Mesothelioma | Status: UNKNOWN